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β-Adrenergic agonistsBoth endothelin-1 (ET-1) and cAMP are implicated for inducing insulin resistance. Since we have shown
previously that there is a crosstalk between ET-1 and cAMP signaling pathways in regulating glucose uptake in
3T3-L1 adipocytes, we extended our investigation in this study on whether they may have a synergistic effect
on inducing insulin resistance. Our results showed that itwas indeed the case. Insulin-stimulated glucose uptake,
phosphorylation of PKB, IRS-1-associated PI3K, and IRS-1 tyrosine phosphorylationwere all inhibitedby ET-1 and
8-bromo cAMP in a synergistic manner. IRS-1 protein levels were similarly decreased by ET-1 and 8-bromo
cAMP, attributable to suppressed mRNA expression. In addition, after correction for the loss in IRS-1 protein,
the inhibition of insulin-stimulated IRS-1 tyrosine phosphorylation or IRS-1-associated PI3K was mainly caused
by cAMP. Moreover, whereas IRS-2 protein levelswere increased by cAMP or ET-1 plus cAMP, insulin-stimulated
IRS-2-associated PI3K activities were abolished by both treatments. Furthermore, ET-1 and β-adrenergic agonists
had similar synergistic inhibition on insulin-stimulated glucose uptake. In conclusion, we have shown that ET-1
and cAMP may synergistically induce insulin resistance in adipocytes via inhibiting IRS-1 expression as well as
insulin-stimulated IRS-1/IRS-2 activities.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
ET-1 is a 21-amino acid polypeptide mainly secreted by endothelial
cells. Besides being a potent vasoconstrictor [1], ET-1 is closely related to
insulin resistance. Elevated plasma concentrations of ET-1 has been
reported in diabetes mellitus [2], essential hypertension [3], aging [4],
uremia [5], post-surgery [6], and obesity [7], all of which are known to
be accompanied by insulin resistance [8–13]. Indeed, ET-1 was shown
to induce insulin resistance in humans and rats [14–16] and inhibit
insulin-stimulated glucose uptake in muscle cells [17] and adipocytes
[18,19].
β-Adrenergic agonists have been well known for impairing insulin
action and their inhibitory effects seem to bemediated by the signaling
messenger cAMP [20–23]. In concord, glucagon and parathyroid hor-
mone (PTH) have also been shown to inhibit insulin-stimulated glucose
transport via cAMP [24,25]. Thus it appears that elevated cAMPmay be
one of the factors which induce insulin resistance.
We have shown previously that ET-1 and cAMP have a synergistic
effect on GLUT1-mediated glucose uptake in 3T3-L1 adipocytes [26,
27]. In the present study, we further address the question if ET-1 and
cAMP may have a synergistic effect on inducing insulin resistance.
Using 3T3-L1 adipocytes as an insulin target, we show that ET-1 and
cAMP indeed have a synergistic effect on inhibiting insulin-stimulatedglucose uptake. The augmented inhibition seems to be attributable
to decreased insulin-stimulated phosphorylation of protein kinase B
(PKB) as a result of enhanced inhibition of insulin receptor substrate-1
(IRS-1) gene expression as well as inhibition of IRS-1/IRS-2 activities.
2. Materials and methods
2.1. Materials
2-Deoxy-D-glucose (2-deoxyglucose), dithiothreitol (DTT), dexa-
methasone, phenylmethylsulfonyl ﬂuoride (PMSF), 3-isobutyl-1-
methylxanthine (IBMX), epinephrine, norepinephrine, 8-bromo cAMP
and insulin were obtained from Sigma Chemicals (St. Louis, MO, USA).
ET-1 was purchased from Peninsula Laboratories (San Carlos, CA, USA).
Antibodies against IRS-1, IRS-2, p85 (a subunit of phosphatidylinositol-3
kinase (PI3K)) and phosphotyrosine were obtained from Millipore
Upstate (Billerica, MA, USA). Antibodies against PKB and phospho-PKB
(S473) were purchased from Cell Signaling (Boston, MA, USA). [3H]2-
deoxyglucose (8 mCi/mmol) and [γ-32P]ATP (3000 Ci/mmol) were
obtained from New England Nuclear (Boston, MA, USA).
2.2. Cell culture
3T3-L1cells, obtained fromAmericanTypeCultureCollection (Rockville,
MD, USA), were grown and differentiated into adipocytes in Dulbecco's
modiﬁed Eagle's medium supplemented with 10% heat-inactivated
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earlier [27]. Brieﬂy, 2 days after conﬂuence (day 0), themediumwas re-
moved and freshmedium containing 0.5 mM IBMX and 0.25mMdexa-
methasone was added. After another 3 days, the mediumwas replaced
with fresh culture medium and the cultures were then maintained as
described above. By day 8,more than 90%of the cells have differentiated
into rounded cells with lipid droplets. Day 8–12 differentiated 3T3-L1
adipocytes were used for experiments throughout this study.
2.3. Measurement of glucose transport activity
Glucose transport activity was analyzed by measuring uptake of
[3H]2-deoxyglucose into the cells as described previously [28].
Carrier-speciﬁc uptakewas obtained by correction for nonspeciﬁc diffu-
sion of [3H]2-deoxyglucose into the cells as estimated in the presence of
10 μM cytochalasin B, which accounted for approx. 6–8% of the activity.
2.4. Preparation of cell lysates
After various treatments, cells were washed with phosphate-
buffered saline (PBS) and lyzed in buffer containing 50 mM Tris,
pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.5 mM Na3VO4, 50 mM NaF, 5 mM
Na4P2O7, 1 mM DTT, 10 mM β-glycerophosphate, 0.5% Nonidet P-40,
0.1 mM PMSF and protease inhibitor cocktail (Sigma) for 40 min on
ice. After centrifugation at 20,000×g for 30min at 4 °C to remove the in-
soluble materials and the fat cake, the cell lysates were used for
immunoprecipitation or immunoblot analysis.
2.5. Determination of tyrosine phosphorylation of IRS-1 and
IRS-1-associated PI3K
Immunocomplex obtained from anti-IRS-1 antibody was used for
the assessment of its tyrosine phosphorylation and associated p85, a
subunit of PI3K. Brieﬂy, after cell lysates were incubated with anti-
IRS-1 for 8–12 h at 4 °C, immunoprecipitates were collected by protein
G-Magnetic Beads (Millipore), washed three times with PBS also con-
taining 0.1% Tween 20, and subjected to immunoblot analysis with
anti-IRS-1, anti-phosphotyrosine and anti-p85 antibodies.
2.6. Immunoblot analysis
After 7.5% SDS-polyacrylamide gel electrophoresis (PAGE) under re-
ducing conditions as described earlier [29], samples were transferred to
a nitrocellulose membrane. The amount of speciﬁc protein on the
membrane was then immunodetected by using appropriate primary
and secondary antibodies. The blots were developed by the enhanced
chemiluminescence method (ECL, Millipore). Quantiﬁcation of relative
band intensity was performed by laser scanning densitometry.
2.7. RNA preparation, RT-PCR and real-time PCR
Total cellular RNA was prepared using TRIzol reagent (Invitrogen)
according to the manufacturer's instruction. cDNA synthesis was per-
formed at 65 °C using 2 μg of total RNA of 3T3-L1 adipocytes as the tem-
plate primed with Oligo (dT)15. Aliquots of the cDNAs were subjected
to PCR ampliﬁcation using Platinum™ Tag DNA polymerase under opti-
mal conditions in the presence of appropriate pairs of primers. IRS-1:
(F) 5′-TGAACCTCAGTCCCAACCA-3′, (R) 5′-CAGCCACACATTCTCAAA
GG-3′; IRS-2: (F) 5′-GTAGCCACAGGAGCAACACA-3′, (R) 5′-CAGGCGTG
GTTAGGGAATAA-3′; and β-actin: (F) 5′-CATGTGCAAGGCCGGCTTCG
CG-3′, (R) 5′-CTGGGTCATCTTCTCGCGGT-3′. The PCR products were
analyzed by 2% agarose gel electrophoresis. For real-time PCR, cDNA
was quantiﬁed using TaqMan® Gene Expression Assays (Product No.
Mm00439720_s1 for IRS-1; Mm03038438_m1for IRS-2) (Applied
Biosystems, Foster City, CA, USA).2.8. Assay of IRS-2 associated PI3K activity
Immunocomplex obtained from anti-IRS-2 antibody was used
for the assay of PI3K activity as described earlier [30], using phos-
phatidylinositol and [γ-32P]ATP as the substrates.2.9. Statistical analysis
All experimentswere performed for at least three times. The data are
presented as means ± S.E. Statistical difference was determined by
Student's t-test.3. Results
3.1. Synergistic inhibition of insulin-stimulated glucose transport by
prolonged treatment with ET-1 and cAMP
We showed previously that treatment of 3T3-L1 adipocytes with
ET-1 and 8-bromo cAMP for 8 h only had a minor inhibitory effect on
insulin-stimulated glucose uptake (↓13%, P N 0.05), although enhanced
GLUT1 expression and GLUT1-mediated glucose transport tremendous-
ly [26]. To test the possibility that longer treatmentwith ET-1 and cAMP
may be required to exert signiﬁcant inﬂuence, we treated cell with ET-1
and 8-bromo cAMP for 12, 24, 36 and 48 h, and measured basal and
insulin-stimulated glucose uptake. As shown in Fig. 1A & B, ET-1 alone
increased glucose uptake to approximately 2.4-fold (P b 0.05) of basal
and this enhancing effect lasted for at least 48 h, in accordance with
our earlier ﬁnding that ET-1 enhanced glucose uptake by augmenting
GLUT1 expression [31]. 8-Bromo cAMP alone had little inﬂuence on
basal glucose uptake but it enhanced the stimulatory effect of ET-1 at
8 h and this enhancement declined with time, implying that the syner-
gistic effect of ET-1 and cAMP on GLUT1-mediated glucose transport
does not last for long period of time. On the other hand, while ET-1
alone had only a minor non-signiﬁcant inhibitory inﬂuence on insulin-
stimulated glucose uptake (↓10–14%, P N 0.05, over the period of 48 h)
and cAMP alone only exerted signiﬁcant inhibitory effect at 48 h
(↓30 ± 9%, P b 0.05), a combination of ET-1 and cAMP signiﬁcantly
inhibited insulin-stimulated glucose uptake and this inhibition was
getting stronger with time (↓48 ± 11%, P b 0.02, ↓57 ± 11%, P b 0.02
and ↓70±12%, P b 0.02 at 24, 36 and 48 h, respectively). The inhibitions
by ET-1 plus cAMP at 24 and 36 h are signiﬁcantly greater than the sum
of inhibitions caused by ET-1 and cAMP alone (P b 0.05). Thus ET-1 and
cAMP may exert a synergistic inhibition of insulin-stimulated glucose
transport in a time-dependent manner.3.2. Effect of ET-1 and cAMP on insulin-stimulated PKB phosphorylation
It is well known that insulin-stimulated glucose transport involves
sequential events from activation of insulin receptor tyrosine kinase,
tyrosine phosphorylation of IRS-1, activation of PI3-kinase, activation
of PKB, and phosphorylation of AS160, to translocation of GLUT4 from
intracellular compartments to plasma membranes [32–34], and PKB
seems to play a critical role in this process [35,36]. To examine if PKB
was inhibited by ET-1 and cAMP, we treated cells with ET-1, 8-bromo
cAMP and both for 48 h and determined the insulin-stimulated phos-
phorylation of PKB at S473, an index of PKB activation [37]. As shown
in Fig. 2A & B, whereas ET-1 alone had little effect, it signiﬁcantly
enhanced the inhibition caused by cAMP from 30 ± 7% (P b 0.05) to
61 ± 7% (P b 0.01). The extent of decrease in insulin-stimulated phos-
phorylation of PKB is comparable to that in insulin-stimulated glucose
uptake in the presence of ET-1 and cAMP, suggesting that the inhibitory
effect of ET-1 and cAMP should be exerted at PKB or its upstream
signals.
Fig. 1. (A) Time-dependent effect of ET-1, 8-bromo cAMP and a combination of both on glucose transport. After 3T3-L1 adipocytes were treated with none, 10 nM ET-1, 0.5 mM 8-bromo
cAMP or ET-1 + 8-bromo cAMP for indicated times, cells were washed and incubated in the absence (basal) or presence of 100 nM insulin for 30 min and measured for 2-deoxyglucose
(2-DG) uptake. (B) Insulin-stimulated glucose uptake in (A)was re-plotted after being corrected for the basal. For each time point, control is the value obtained in the absence of ET-1 and
cAMP. *P b 0.05, **P b 0.02 compared with the corresponding control.
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The initial event in insulin signaling pathway is the tyrosine
phosphorylation of insulin receptor-β in response to insulin (auto-
phosphorylation) [38]. To test the possibility that inhibition of insulin
receptor autophosphorylation might be the primary effect of ET-1
and cAMP, 3T3-L1 adipocytes were treated with ET-1 + 8-bromo
cAMP for 48 h, and analyzed for insulin-stimulated IR-β (Y1162/
1163) phosphorylation as well as PKB phosphorylation. As shown in
Fig. 3A, whereas ET-1 plus cAMP inhibited insulin-stimulated PKB
phosphorylation, it actually increased insulin-stimulated insulin recep-
tor phosphorylation. The increase in insulin receptor autophosphoryla-
tion most likely reﬂects the effect of ET-1 plus cAMP on enhancing
the insulin receptor amount. Further investigation indicated that
cAMP alone augmented insulin receptor amount; ET-1 had essentially
no inﬂuence, either alone or in combination with cAMP (Fig. 3B).
Thus it appears that the inhibitory effect of ET-1 and cAMP on
insulin action should be some step downstream of insulin receptor
autophosphorylation.3.4. Effect of ET-1 and cAMP on insulin-stimulated tyrosine phosphorylation
of IRS-1 and IRS-1-association with PI3K
Since IRS-1 is downstream of insulin receptor and upstream of PKB
in insulin signaling cascades, and a well-known target for insulin resis-
tance [34], we treated cells with ET-1, 8-bromo cAMP and both for 48 h
and determined their effects on insulin-stimulated tyrosine phosphory-
lation of IRS-1 and IRS-1-associated p85 (as an index for PI3K associa-
tion). As shown in Fig. 4A & B, cAMP alone decreased total IRS-1
protein amount by 17 ± 5% (P b 0.05), and insulin-stimulated tyrosine
phosphorylation of IRS-1 and IRS-1-associated PI3K by 43 ± 7%
(P b 0.01) and 41 ± 6% (P b 0.01), respectively. On the other hand,
whereas ET-1 alone had no signiﬁcant inﬂuence, it potentiated the dete-
riorating effect of cAMP on IRS-1 protein content as well as insulin ac-
tions on IRS-1 tyrosine phosphorylation and IRS-1-associated p85. In
the presence of both ET-1 and cAMP, IRS-1 protein content, insulin-
stimulated IRS-1 tyrosine phosphorylation and IRS-1-associated p85
were decreased by 64 ± 6% (P b 0.01), 76 ± 7% (P b 0.01) and 79 ±
10% (P b 0.01), respectively. To get a better evaluation of the effects of
Fig. 2. (A) Effect of ET-1, 8-bromo cAMP and a combination of both on insulin-stimulated
PKB phosphorylation. After 3T3-L1 adipocytes were treated with none, 10 nM ET-1,
0.5mM8-bromo cAMP or ET-1+8-bromo cAMP for 48h, cellswerewashed and incubat-
ed in the absence (basal) or presence of 100 nM insulin for 10 min. Cell lysates were pre-
pared and subjected to immunoblot analysis using antibodies against PKB and phospho-
PKB (S473). β-Actin was used as the internal control. (B) Blots in (A) are quantiﬁed by
laser scanning densitometry. The results from three separate experiments are presented
using the value obtained in the absence of ET-1 and cAMP as the control. *P b 0.05,
**P b 0.01 compared with the control.
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and IRS-1-associated p85 per se, the data of Fig. 4Bwere re-plotted after
correction for the amount of IRS-1 (Fig. 4C). Regardless of the treat-
ments, the extent of inhibition of insulin-stimulated tyrosine phosphor-
ylation of IRS-1 is close to that of IRS-1-associated p85, indicating the
correlation between these two events. Importantly, there is no signiﬁ-
cant difference between the inhibition caused by cAMP alone or byFig. 3. (A) Effect of ET-1 plus cAMP on insulin receptor (IR) autophosphorylation. 3T3-L1
adipocytes were incubated in the absence and presence of ET-1 + 8-bromo cAMP for
48 h, and analyzed for insulin-stimulated IR-β phosphorylation and PKB phosphorylation
by immunoblot analysis using antibodies against IR-β, phospho-Y1162/1163 IR-β,
PKB and phospho-S473 PKB. (B) Effect of ET-1, 8-bromo cAMP and both on IR-β amounts.
3T3-L1 adipocytes were incubated in the absence and presence of ET-1, 8-bromo cAMP or
ET-1 + 8-bromo cAMP for 48 h, and analyzed for IR-β amounts. β-Actin was used as the
internal control.
Fig. 4. (A) Effect of ET-1, 8-bromo cAMP and a combination of both on insulin-stimulated
tyrosine phosphorylation of IRS-1 and IRS-1-associated PI3K. Experiments were
performed as described in the legend to Fig. 2A. Cell lysates were divided into two parts.
One part was subjected to immunoblot analysis using antibodies against IRS-1 and p85.
The other part was immunoprecipitated with anti-IRS-1 antibody. The immunocomplex
obtained was subjected to immunoblot analysis with anti-IRS-1, anti-phosphotyrosine
and anti-p85 antibodies. (B) Blots in panel (A) are quantiﬁed by laser scanning densitom-
etry. The results from three separate experiments are presented using the value obtained
in the absence of ET-1 and cAMP as the control. *Values are signiﬁcantly different from the
corresponding control. #Values are signiﬁcantly different from the corresponding IRS-1.
(C) The data in (B) were re-plotted after correction for the amounts of IRS-1. *Values are
signiﬁcantly different from the corresponding control.ET-1 plus cAMP, on insulin-stimulated IRS-1 tyrosine phosphorylation
(36 ± 7% vs. 36 ± 6%) or IRS-1-associated p85 (33 ± 7%, vs. 41 ±
8%), implying that ET-1 has no potentiating effect on cAMP-evoked
inhibition of insulin-stimulated IRS-1 tyrosine phosphorylation or
IRS-1-associatedPI3K. Similar resultswereobtained if immunoprecipitated
p85 was used to estimate the formation of IRS-1/PI3K complex or tyro-
sine phosphorylation of IRS-1 (Supplementary Fig. S1). Taken together,
these results suggest that whereas cAMP decreases insulin-stimulated
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reducing IRS-1 protein amount.3.5. Time-dependent effect of ET-1 and cAMP on IRS-1 protein and
mRNA levels
Given that the synergistic inhibition of insulin-stimulated glucose
uptake is time-dependent (Fig. 1B) and the decrease in IRS-1 protein
amount seems to play a major role in the presence of both ET-1 and
cAMP, we measured time-dependent effect of ET-1 and 8-bromo
cAMP on IRS-1 protein levels. As shown in Fig. 5A, while the effect of
cAMP was relatively slow and to a much lesser extent (↓24 ± 7%,
P b 0.05, at 48 h), ET-1 plus cAMP reduced IRS-1 protein amount at a
faster pace and to a much greater extent. IRS-1 protein declined by
approximately 25% (P b 0.02) at 12 h and 77 (P b 0.01) at 48 h. Since
ET-1 alone had no signiﬁcant effects (Figs. 1B & 4B), the results indicate
that the cooperation of ET-1 and cAMP facilitates the down-regulation
of IRS-1 protein content, which plays an essential role in reducing
insulin-stimulated glucose uptake.
Since IRS-1 protein is relatively stable (with a half-life of 10–14 h)
[39,40] and the decrease in IRS-1 protein abundance is rather slow in
the presence of ET-1 and cAMP (see above), we further measured the
time-dependent effect of ET-1 and cAMP on IRS-1 mRNA levels. As
shown in Fig. 5B, while cAMP alone could reduce IRS-1 mRNA levels at
a slow pace, ET-1 plus cAMP rapidly decreased IRS-1 mRNA to approx-
imately 25% of control at 12 h and it remained gradually lower to
approximately 10% of control at 48 h. Assuming that IRS-1 protein
synthesis is tightly coupled to its mRNA levels, we estimate that in the
presence of both ET-1 and cAMP, IRS-1 protein would degrade with a
half-life of approximately 17 h, if all mRNA expression was terminated.
This value is very close to that reported in the presence of transcription
inhibitor actinomycin D [40]. Thus the decrease in IRS-1 protein levelsFig. 5. (A) Time-dependent effect of 8-bromo cAMP and ET-1 plus 8-bromo cAMPon IRS-1 prote
or 10 nMET-1+ 8-bromo cAMP for indicated times, cell lysateswere prepared and subjected to
laser scanning densitometry. The results from three separate experiments are presented using
control. (Lower panel) A semi-log plot is used to estimate the half-life (t1/2) of IRS-1 in the pre
ET-1 plus 8-bromo cAMP on IRS-1 mRNA levels. Experiments were performed as described in t
by RT-PCR and real-time PCR. The results from three separate experiments are presented usingcan be reasonably accounted for by the strong inhibitory effect of ET-1
plus cAMP on IRS-1 mRNA expression.
3.6. Time-dependent effect of ET-1 and cAMP on IRS-2 protein and
mRNA levels
In adipocytes, IRS-2 seems to partially compensate for impaired
insulin action on IRS-1 [41]. Since IRS-2 expression was reported to be
augmented by cAMP in pancreatic β-cell [42], we determined IRS-2
expression in response to 8-bromo cAMP or ET-1 plus 8-bromo cAMP
in 3T3-L1 adipocytes. As shown in Fig. 6A, cAMP increased IRS-2 protein
amount in a time-dependent manner, reaching a plateau at 36–48 h. In
accordance, IRS-2 mRNA levels were also enhanced by cAMP in a time-
dependent manner, reaching a peak at 36 h and declining thereafter
(Fig. 6B). Nevertheless, the increasing pace in IRS-2 protein levels was
much faster than that in IRS-2 mRNA levels, implying that cAMP
may exert its enhancing effect at both transcriptional and post-
transcriptional levels. On the other hand, ET-1 does not seem to play
any signiﬁcant role in the regulation of IRS-2 expression, either alone
(data not shown) or in combination with cAMP.
3.7. Inhibition of insulin-stimulated IRS-2-associated PI3K activity by cAMP
Both IRS-1 and IRS-2 are capable of transducing the insulin signal
from activation of insulin receptor to downstream PKB [43]. The obser-
vation that IRS-2 protein levels are elevated by cAMP raises the issue
whether the increased IRS-2 amount could help compensate for the
loss in IRS-1 function? Nevertheless, the results from measuring IRS-2-
associated PI3K activities in cells treated with ET-1 and cAMP eliminate
this possibility. As shown in Fig. 7, while ET-1 alone had no inﬂuence,
treatment with cAMP or ET-1 plus cAMP for 48 h abolished insulin-
stimulated IRS-2-associated PI3K activities. Therefore, although cAMPin levels. (Upper panel) After 3T3-L1 adipocyteswere treatedwith 0.5mM8-bromo cAMP
immunoblot analysis using antibody against IRS-1. (Middle panel) Blots are quantiﬁed by
the value at time zero as the control. *P b 0.05, **P b 0.02, ***P b 0.01 compared with the
sence of both ET-1 and 8-bromo cAMP. (B) Time-dependent effect of 8-bromo cAMP and
he legend to (A) except that total RNA was extracted and estimated for IRS-1 mRNA levels
the value at time zero as the control. *P b 0.05, **P b 0.01 compared with the control.
Fig. 6. (A) Time-dependent effect of 8-bromo cAMP and ET-1 plus 8-bromo cAMPon IRS-2 protein levels. (Upper panel) After 3T3-L1 adipocyteswere treatedwith 0.5mM8-bromo cAMP
or 10 nM ET-1+ 8-bromo cAMP for indicated times, cell lysates were prepared and subjected to immunoblot analysis using antibody against IRS-2. (Lower panel) Blots are quantiﬁed by
laser scanning densitometry. The results from three separate experiments are presented using the value at time zero as the control. *P b 0.05, **P b 0.02, ***P b 0.01 compared with the
control. (B) Time-dependent effect of 8-bromo cAMP and ET-1 plus 8-bromo cAMP on IRS-2 mRNA levels. Experiments were performed as described in the legend to (A) except that
total RNA was extracted and estimated for IRS-2 mRNA levels by RT-PCR and real-time PCR. The results from three separate experiments are presented using the value at time zero as
the control.
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help PKB activation in response to insulin, mainly due to the inhibition
of IRS-2 function by cAMP.3.8. Synergistic inhibition of insulin-stimulated glucose transport by ET-1
and β-adrenergic agonists
It is well known that β-adrenergic agonists exert their inﬂuence in
adipocytes via a cAMP pathway [44]. The ﬁnding that ET-1 and cAMP
had a synergistic interaction in inhibiting insulin-stimulated glucose
transport prompted us to examine if the β-adrenergic agonists could
act synergistically with ET-1 to inhibit insulin-stimulated glucose up-
take. As shown in Fig. 8A & B, whereas epinephrine or norepinephrineFig. 7. Inhibition of insulin-stimulated IRS-2-associated PI3K activity by 8-bromo cAMP
and ET-1 plus 8-bromo cAMP. Cells were treated exactly as described in the legend to
Fig. 5A. The immunocomplex obtained with anti-IRS-2 antibody was used for the assay
of PI3K activity as described in Materials and methods section and the product, phos-
phatidylinositol-3-32P (PI3-P) was developed by thin layer chromatography on a Silica
gel plate. Two other experiments showed similar results.
Fig. 8. Effect of ET-1 and (A) epinephrine or (B) norepinephrine on glucose uptake. 3T3-L1
adipocytes were treated with (A) ET-1 and epinephrine or (B) ET-1 and norepinephrine
for 48 h, and assayed for basal and insulin-stimulated glucose uptake. *Values are
signiﬁcantly different from the corresponding control measured in the absence of ET-1
and β-adrenergic agonist. #Values are signiﬁcantly different from the corresponding basal.
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and norepinephrine acted synergistically with ET-1 to inhibit
insulin-stimulated glucose uptake by 66 ± 13% (P b 0.02) and
64 ± 9% (P b 0.01), respectively. Thus similar to ET-1 and cAMP, ET-1
and β-adrenergic agonists also induce a synergistic inhibition of
insulin-stimulated glucose uptake. It further implies that there is a
cross-talk between ET-1 and β-adrenergic signaling pathways in the
regulation of insulin action in adipocytes.
4. Discussion
Themajor ﬁnding of this study is the synergistic inhibition of insulin
action by ET-1 and β-adrenergic agonists (via cAMP) by a complex
mechanism. It involves synergistic inhibition of IRS-1 expression
by ET-1 and cAMP (the dominant effect) as well as the inhibition of
IRS-1/IRS-2 activities by cAMP. Although the cAMP inhibition of IRS-1
function is rather mild (↓35%), insulin-stimulated IRS-2-associated
PI3K activity is completely inhibited by cAMP. This inhibition of IRS-2
function by cAMP plays an essential role in the synergistic inhibition
of insulin action by ET-1 and cAMP, since ET-1 plus cAMP dramatically
increases IRS-2 expression by approximately 4-fold. Therefore, with
cAMP inhibition of IRS-2 activity, the synergistic effect of ET-1 and
cAMP on inhibiting insulin action becomes manifested.
At present, the mechanism of inhibiting IRS-1 expression by ET-1
and cAMP is unknown. Although the pivotal role of IRS-1 in insulin sig-
naling and insulin resistance has been extensively investigated and
established, relatively few studies regarding the regulation of IRS-1
gene expression have been reported. Dexamethasone [39], PTH [25],
and adipocytokines [45] including IL-1β [46], IL-6 and tumor necrosis
factor-α (TNF-α) [47] have all been reported to down-regulate IRS-1
mRNA levels in adipocytes. Thus there exists a possibility that the effect
of ET-1 plus cAMP could be indirectly mediated by released IL-1β, IL-6
or TNF-α. Since the release of IL-6 is synergistically induced by ET-1
and cAMP [48], it would be of interest to test if IL-6 is involved in the
synergistic inhibition of IRS-1 gene expression by ET-1 and cAMP.
On the other hand, IRS-1 promoter is subjected to both positive and
negative regulation [49,50] and contains many putative AP-1, Sp1 and
AP-2β binding sites [51,52]. While AP-2β [52], ATRA [53] and BRCA1
[54] are implicated as negative regulators, AP-1 cooperating with
SRC-3 [55] or Sp1 with estrogen receptor [51] seems to enhance the
promoter activity. Thus the repressing effect of ET-1 plus cAMP on
IRS-1 expression could potentially be exerted through potentiating the
negative or inhibiting the positive regulatory factors. These possibilities
are currently under investigation.
Besides adipocytes, adipose tissue contains blood vessels and is in-
nervated by sympathetic nerves [56]. Accordingly, adipocytes in vivo
are subjected to inﬂuences from ET-1 released from neighboring endo-
thelial cells, norepinephrine released from nerve endings and circulat-
ing epinephrine. The ﬁnding in this study thus raises the possibility
that under certain conditions whereas plasma levels of both ET-1 and
catecholamines are sustainedly high, insulin action in adipocytes
would be impaired and might lead to some diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.06.026.
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